Adma Biologics, Inc.
ADMA· Nasdaq
Released Aug 9, 2023, after the close
10-Q filed Aug 9, 2023, 40 days after period end · 0001140361-23-038843
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $60.12M | $33.91M | $17.83M | $7.79M |
| Net Income | -$6.37M | -$13.76M | -$18.91M | -$20.18M |
| EPS Diluted |
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
| -$0.03 |
| -$0.07 |
| -$0.15 |
| -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.